Trials / Active Not Recruiting
Active Not RecruitingNCT07014280
Bevacizumab Versus Triamcinolone Acetonide for the Treatment of Keloids.
Efficacy of Intralesional Bevacizumab Versus Intralesional Triamcinolone Acetonide Injection in the Treatment of Keloids.
- Status
- Active Not Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 28 (actual)
- Sponsor
- Kasr El Aini Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study compares the efficacy and safety of intralesional bevacizumab versus corticosteroids for the treatment of keloids. Assessment will be done clinically by the use of Modified Vancouver Scar Scale. Erythema index will be measured by spectrophotometry. The levels of Vascular Endothelial Growth Factor, collagen type 1 and collagen type 3 in the lesions before and after each treatment modality.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bevacizumab | anti-VEGF |
| DRUG | Triamcinolone Acetonide | corticosteroid |
Timeline
- Start date
- 2023-09-01
- Primary completion
- 2024-09-01
- Completion
- 2025-07-01
- First posted
- 2025-06-10
- Last updated
- 2025-06-10
Locations
1 site across 1 country: Egypt
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07014280. Inclusion in this directory is not an endorsement.